Here’s Why Sanofi (SNY) is Outperforming Its Industry Of Late
Sanofi ’s SNY shares have outperformed the industry this year so far. It has risen 7.1% in the said time frame against the industry’s decrease of 0.8%. The company’s performance has been backed by quite a few positive developments on the regulatory and pipeline front mainly related to its new successful drug Dupixent, strong performance of its Specialty Care segment, as well as a decent earnings performance in the first half of the year. […]